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Background and objective: Lanreotide is a somatostatin analogue used for the treatment of acromegaly andAbstract
neuroendocrine tumours. The objective of this study was to develop a pharmacokinetic model for the sustained-
release formulation lanreotide Autogel® after deep subcutaneous administration in healthy subjects, and to
explore the potential effect of covariates, especially sex and dose.
Subjects and methods: This was an open-label, single-centre, randomized, dose-ranging, parallel-group study,
with a follow-up period of 4–7 months following drug administration in healthy subjects. Healthy Caucasian
subjects aged 18–45 years were included. Subjects received a rapid intravenous bolus of 7 µg/kg of an
immediate-release formulation of lanreotide (lanreotide IRF). After a 3-day washout period, participants were
randomized to receive a single deep subcutaneous injection of lanreotide Autogel® at a dose of 60, 90 or 120 mg.
Pharmacokinetic and statistical analysis: Blood samples for lanreotide determination were obtained during
the first 12 hours after the intravenous bolus injection and during the 4- to 7-month follow-up period after deep
subcutaneous administration of lanreotide Autogel®. Data after intravenous and subcutaneous administration
were fitted simultaneously using the population approach in NONMEM® version VI software. The model was
validated externally using data from patients with acromegaly.
Results: In total, 50 healthy subjects (24 women and 26 men) received a single intravenous dose of lanreotide
IRF. Of these, 38 subjects (18 women and 20 men) received a single subcutaneous dose of lanreotide Autogel®
3 days after intravenous lanreotide IRF. The disposition of lanreotide was described by a three-compartment
open model. The estimates of the total volume of distribution and serum clearance were 15.1 L and 23.1 L/h,
respectively. The estimates of interindividual variability were <40%. To evaluate lanreotide Autogel®
pharmacokinetics, the absorption rate was modelled to decrease exponentially as a function of the natural
logarithm of time. The absolute bioavailability after deep subcutaneous administration of lanreotide Autogel®
was 63%. The rate of absorption and bioavailability of lanreotide Autogel® were independent of the adminis-
tered dose in the range from 60 to 120 mg, and no significant effect of covariates (sex, dose, age or bodyweight)
was found (p > 0.05).
Conclusions: Population analysis allows a full description of the disposition of lanreotide after rapid intravenous
bolus administration of lanreotide IRF (7 µg/kg) and the pharmacokinetics of lanreotide Autogel® after a single
deep subcutaneous injection (60, 90 or 120 mg) in healthy subjects. The model-based simulations provide
support for the feasibility of extending the dosing interval for lanreotide Autogel® to 56 days when given at
120 mg. The absorption profile of lanreotide Autogel® was independent of the dose and was not affected by sex.
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Background meters, the design included a rapid intravenous bolus injection of
an immediate-release formulation of lanreotide (lanreotide IRF).
Lanreotide is a synthetic octapeptide somatostatin analogue
Study Participants and Methodsused to treat acromegaly and neuroendocrine tumours; it binds
preferentially to pituitary somatostatin receptors, inhibits growth This was an open-label, single-centre, randomized, pharmaco-
hormone secretion and reduces insulin-like growth factor I kinetic phase I study involving three parallel groups of healthy
levels.[1] An earlier extended-release lanreotide formulation based subjects. The study was conducted according to the Declaration of
on microparticles of lactide-glycolide copolymer allowed the re- Helsinki and Good Clinical Practice guidelines. The protocol was
lease of the peptide over 7–14 days after intramuscular administra- reviewed and approved by the local ethics committee, and all
tion.[2] The development of lanreotide Autogel® (Somatuline participants gave their written informed consent.
Autogel®, Beaufour Ipsen, Dreux, France), a supersaturated solu-
tion containing only lanreotide and water, for subcutaneous injec- Participants
tion, extended the duration of release to a more convenient dosing
Inclusion of 54 healthy subjects was planned. Caucasian meninterval of at least 28 days.[3] This formulation, supplied as a
and women fulfilling the following criteria were included: age
ready-to-use preparation (of 60, 90 or 120 mg) in pre-filled
between 18 and 45 years; bodyweight within 10% of the idealpolypropylene syringes, has good effectiveness and is well tolerat-
height/frame; normal physical and laboratory test results; womened in patients; the main side-effects, which are of a gastrointestinal
with a negative pregnancy test who were not breastfeeding and
nature,[4-6] have been similarly reported with other somatostatin
who were using appropriate contraceptive methods; willingnessanalogues given at therapeutic doses.[7]
and ability to understand and sign an approved informed consentA population model has recently been developed that relates
form.lanreotide serum concentrations at steady state after administration
The exclusion criteria were a history of alcohol (ethanol) or
of lanreotide microparticles or lanreotide Autogel® with growth
drug abuse; smoking of >10 cigarettes/day; history of chole-hormone levels, estimating parameters associated with baseline
lithiasis or gastrointestinal, renal, hepatic, pulmonary or cardio-growth hormone levels, hormonal effectiveness and potency, as
vascular disease; history of epilepsy, asthma, diabetes mellitus,
well as their corresponding degree of interindividual variability
psychosis or glaucoma; history of an allergic response to lanreo-(IIV).[8] The pharmacodynamic properties of lanreotide were inde-
tide or related drugs; blood donation of ≥250 mL or participationpendent of the formulation. However, a pharmacokinetic model
in a clinical trial in the 3 months before study initiation; practising
relating the lanreotide serum concentration to the dose and time
vegetarian diet, abnormal diet or substantial changes in eatinghas not been developed; so far, only descriptors such as the
habits within the previous 4 weeks; treatment with any known
maximum serum concentration (Cmax), minimum serum concen-
enzyme-inhibiting or enzyme-inducing agents in the 4 weekstration (Cmin) and area under the serum concentration-time curve
before study medication; and positive tests for HIV and/or hepati-(AUC) have been reported.[4,9] Such a model, when combined with
tis B and C.the pharmacodynamic model, could be used to explore the rela-
tionship between growth hormone levels and time in different
Drug Administration and Sample Collection
clinical scenarios, taking into account the IIV in both pharmaco-
Participants received a single intravenous dose (7 µg/kg) ofkinetic and pharmacodynamic processes. Therefore, the main ob-
lanreotide IRF by rapid intravenous bolus injection (less thanjective of the current analysis was to develop a population pharma-
10 seconds), followed by 3 days of washout and then randomiza-cokinetic model after a single deep subcutaneous injection of
tion to one of three single deep subcutaneous doses of lanreotidelanreotide Autogel®, quantifying the degree of IIV in the pharma-
Autogel® (60, 90 or 120 mg) administered to the superior-externalcokinetic parameters. Differences in the pharmacokinetic proper-
quadrant of the buttock. Lanreotide was administered in the morn-ties between males and females in the case of the subcutaneous
ing, and fasting conditions were not required.administration could be expected because of higher subcutaneous
fat levels in women.[10] Therefore, the study of the potential effect Lanreotide IRF was obtained by reconstituting lanreotide ly-
of covariates of sex, in addition to the dose level, was also part of ophilisate with diluent (mannitol 40 mg/1 mL water for injections)
the main objective of the analysis. To estimate the absolute bio- immediately before administration. The lanreotide Autogel® for-
availability of lanreotide Autogel® and serum disposition para- mulation consists of lanreotide acetate and water (lanreotide base,
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0.246 mg/mg of solution); the hydration of the peptide leads to the difference in the MOFV of 3.84 and 6.63 points between two
formation of a supersaturated solution. nested models differing by one parameter was considered signif-
icant at the 5% and 1% levels, respectively. Since some ofBlood samples for determining serum lanreotide concentrations
the models that were compared were not nested, the MOFVwere obtained at the following times after the intravenous bolus
was not used directly for comparative purposes, and the valueinjection: at 0, 5, 15 and 30 minutes, then at 1, 1.5, 2, 4, 6, 8 and 12
of the Akaike Information Criteria (AIC)[14] computed ashours. After deep subcutaneous administration, samples were tak-
MOFV + 2 × Np, where Np is the number of the parameters in theen for at least 6 months at 0, 1, 2, 4, 6, 8 and 12 hours during the
model, was used instead. The model with the lowest value of thefirst day after administration and then on days 2, 3, 4, 5, 7, 14, 21,
AIC, given that the precision of the model parameters and data28, 35, 42, 49, 56, 70, 84, 98 and 112, and afterwards if necessary,
description was adequate, was selected.until a serum concentration below the lower limit of quantification
was reached. Drug disposition was described with compartmental models
parameterized in apparent volumes of distribution, and distribu-
Determination of Serum Lanreotide Concentrations tion and elimination clearances. Different absorption models,[15]
including time-dependent absorption rate constants (ka), theA previously validated radioimmunoassay (RIA) procedure Weibull model[16] and the transit compartment model,[17] were
was used to determine serum lanreotide concentrations.[9] The
tested to describe the absorption process after administration of
lower limit of quantification was 0.078 ng/mL, and the overall lanreotide Autogel®.
precision (inter- and intra-assay), expressed as the coefficient of
Demographic characteristics (age, bodyweight, sex) and the
variation (CV), was 2.3–13.6% for concentrations between 0.1 and dose level were first investigated one by one for any potential
10 ng/mL.
effect of covariates on all parameters associated with IIV. Signif-
icant covariates were then incorporated (starting with the covariate
Data Analysis
leading to the largest drop in the MOFV) one at a time until the full
covariate model was obtained. If a covariate was added but did notAll analyses were performed under the population approach
cause a significant decrease in the MOFV, it was removed. Thisusing the Laplacian numerical estimation method with interaction
was followed by a backward-elimination process, wherebyand the nonparametric option implemented in NONMEM® ver-
covariates that were found not to be significant were dropped onesion VI software (Icon Development Solutions, Ellicott City, MD,
by one until no more could be eliminated. The levels of signifi-USA).[11]
cance used during the forward inclusion and backward eliminationAll observations were fitted simultaneously; however, in the
were 5% and 1%, respectively.first step, the model describing the disposition characteristics of
Model parameters were expressed as the corresponding esti-lanreotide in serum was developed using only the data obtained
mate with the relative standard error (RSE; i.e. the ratio betweenafter intravenous administration. Then the disposition model para-
the standard error provided by NONMEM® and the parametermeters were re-estimated when the intravenous and subcutaneous
estimate). The degree of IIV was expressed as the %CV and theobservations were fitted together. In the analyses, the data were
additive residual variability as the standard deviation.logarithmically transformed. Approximately 10% of the observa-
A predictive check was used to assess the performance of thetions at later times after administration were below the lower limit
selected population model by looking at the Cmax of lanreotide andof quantification (BLQ). BLQ observations were kept in the
the AUC from time zero to time of the last measurable concentra-dataset and were treated as censored observations (according to
tion (AUClast). One thousand studies were simulated with themethod 3 in Beal).[12] The method used to handle BLQ observa-
selected pharmacokinetic model, and for each simulated dataset,tions in the current analyses was implemented in NONMEM®
the mean Cmax and AUClast were calculated for each dose levelversion VI based on recent documentation.[13] IIV was modelled
and sex. Then the overall mean values of the Cmax and AUClastexponentially, and residual variability was initially modelled with
across the 1000 simulated studies were computed, as well as thea combined error model; if one of the components (additive or
2.5th and 97.5th percentiles, and compared with the observedproportional) of the residual error was negligible, it was deleted
mean values.from the model.
Model selection was done using the minimum objective func- The final model was further evaluated internally and externally
tion value (MOFV), provided by NONMEM®, as a guide. A using the visual predictive check method.[18] For each dose level,
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1000 virtual individuals were generated on the basis of the esti-
mates of the fixed- and random-effect parameters obtained from
the selected model. The intervals including 95% of the simulated
concentrations and the profile corresponding to the median were
constructed and represented together with (i) the observed concen-
tration values from the healthy subjects (internal validation) and
(ii) the serum lanreotide values obtained from a phase II, multicen-
tre, double-blind, placebo-controlled, repeated-dose, dose-ranging
trial involving 105 patients with acromegaly (external valida-
tion).[19] The schedule corresponding to the fixed dose part of this
phase II study consisted of three phases: (i) washout (weeks –12 to
0) – required only for patients who had been treated previously;
(ii) double-blind, placebo-controlled (weeks 0–4) – a single deep
subcutaneous injection of placebo or lanreotide Autogel® 60, 90 or
120 mg; (iii) single-blind, fixed-dose (weeks 4–20) – four consec-
utive deep subcutaneous injections of lanreotide Autogel® 60, 90
or 120 mg every 28 days. Blood samples for serum lanreotide
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Fig. 1. Individual serum lanreotide concentrations following a rapid intrave-
nous (IV) bolus dose of 7 µg/kg of the immediate-release formulation (IRF)
of lanreotide (a) or deep subcutaneous (SC) administration of lanreotide
Autogel® at doses of 60 mg (b), 90 mg (c) or 120 mg (d).
determination were taken 4 weeks after the first injection and 1, 2,
3 and 4 weeks after the third or fourth lanreotide Autogel® withdrew consent after other subjects described gastrointestinal
injection.[19] AEs). Therefore, 38 subjects were randomized to receive a single
subcutaneous dose of lanreotide Autogel®. As one volunteer sub-
sequently withdrew from the study because of a serious AEResults
(described in the Safety section), 37 subjects completed the study
according to the protocol. Table I lists the demographic and design
Study Participants characteristics of the current study.
Fifty healthy subjects received a single intravenous dose of
Description of the Datalanreotide IRF. Twelve subjects withdrew after this dose but
before lanreotide Autogel® was administered (one withdrew be- Individual observed lanreotide serum concentration-time
cause of adverse events [AEs; nausea, vomiting, diarrhoea and profiles for a single intravenous bolus of lanreotide IRF 7 µg/kg
headache]; one because of a concurrent illness [tonsillitis]; and ten (24 women and 26 men) and for a single deep subcutaneous
injection of lanreotide Autogel® (18 women and 20 men; 60 mg,
n = 13; 90 mg, n = 13; 120 mg, n = 12) are shown in figure 1.
Safety
More subjects in the lanreotide Autogel® groups had AEs than
in the lanreotide IRF group, but there were no specific dose-related
trends across the lanreotide Autogel® groups. Gastrointestinal
events were the most frequent AEs in all groups (lanreotide IRF
and lanreotide Autogel®); in particular, nausea in the lanreotide
IRF group, and diarrhoea, abdominal pain, abdominal distension
and vomiting in the lanreotide Autogel® groups. One serious AE
was reported, in which biliary colic occurred approximately
3 months after the single deep subcutaneous dose of lanreotide
Autogel® 60 mg and resolved after cholecystectomy.
Table I. Demographic and study characteristics for healthy subjects and
patients with acromegaly who were included in the study used for the
external model validation
Parameter Healthy Patients with
subjects acromegaly
Age (y)a 27.6 (5.8) 53.3 (13.8)
Bodyweight (kg)a 67.1 (12.4) 83.8 (17.0)
Sex [n (%)]
female 24 (48) 56 (53)
male 26 (52) 49 (47)
Deep subcutaneous dose [n (%)]
60 mg 13 (34) 34 (32)
90 mg 13 (34) 36 (34)
120 mg 12 (32) 35 (33)
a Values are expressed as mean (SD).
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Pharmacokinetic Modelling Once the disposition model for lanreotide was selected, intrave-
nous and subcutaneous data were fitted simultaneously using a
A total of 500 serum samples (109 were BLQ observations)
total of 1404 serum samples (143 were BLQ observations). Thefrom 50 subjects were used to initially select the disposition
concentration-time profiles (figure 1) showed a similar pattern ofpharmacokinetic model of lanreotide after rapid intravenous bolus
drug release for the three dose levels of lanreotide Autogel® and aadministration. The pharmacokinetic profiles from two subjects
limited initial burst effect. The Cmax occurred 7–12 hours afterresembled an extravascular administration and therefore were
injection. The mean Cmax values were 4.2, 8.4 and 6.8 ng/mL fortreated accordingly.
Lanreotide disposition was best described by a three-compart- the 60, 90 and 120 mg doses, respectively. From day 1 to the end
ment open model compared with the one- and two-compartment of the study (98, 112 and 112 days for the 60, 90 and 120 mg
open models (p < 0.01). IIV was significant for total serum doses, respectively), lanreotide serum concentrations decreased
clearance (CL) and the apparent volume of distribution of the gradually according to a pseudo first-order elimination profile,
shallow peripheral compartment (Vp1; p < 0.01). Table II lists the reflecting prolonged release of the active compound from the
results from the four main models fitted to the intravenous data. depot.
Inclusion of IIV on the rest of the disposition parameters did not
Table II lists the main results obtained during the selection oflead to a significant decrease in the MOFV (p > 0.05). The off-
the best absorption model. A zero-order absorption rate modeldiagonal elements of the variance-covariance Ω matrix were found
performed significantly worse than model 6 in table II. Modelsto be non-significant (p > 0.05). The residual error was modelled
with an additive model. based on two parallel absorption processes, or on sequential zero
Table II. Results from the key models fitted to the data obtained during the development of the population pharmacokinetic model of lanreotide Autogel® in
healthy subjects
Model Model structure ∆MOFV
Disposition models
1 One compartment; ω2CL,Vc
2 Two compartments; ω2CL,Vc –190a
3 Three compartments; ω2CL,Vp1 –350a
4 Three compartments; ω2CL,Vc,Vp1 –350a
Absorption models
5 First-order absorption model; ω2ka,F
6 First-order absorption model, lag time; ω2ka,F –7.3b
7 Weibull model, lag time; ω2α,β,F –277.1b
8 Transit compartment model; ω2N,MTT,ka,F –35.1b
9 First-order absorption model [ka = kb × e–kc × ln(t)], lag time; ω2kb,kc,F –304.1b
Covariate models
10 Model 9; CL related to sex –0.66c
11 Model 9; F related to sex –0.394c
12 Model 9; kb related to sex –3.16c
13 Model 9; F related to dose 0.0c
a Change in MOFV with respect to model 1.
b Change in MOFV with respect to model 5.
c Change in MOFV with respect to model 9.
α = scale parameter in the Weibull model; β = shape parameter in the Weibull model; ∆MOFV = change in the minimum objective function value provided
by NONMEM®; ω2 = variance of random effects; CL = total serum clearance; F = total bioavailability; ka = first-order absorption rate constant; kb = first-
order absorption rate constant 24 h after administration; kc = first-order rate constant governing the exponential decrease in the kb as a function of ln(t);
MTT = mean transit time; N = number of transit compartments; t = time after drug administration; Vc = apparent volume of distribution of the central
compartment; Vp1 = apparent volume of distribution of the shallow peripheral compartment.
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Models 10–13 in table II list some of the results obtained when
covariates were incorporated into model 9. All of the covariates
tested (bodyweight, age, sex and dose level) elicited only very
marginal decreases in the MOFV with respect to model 9
(p > 0.05), and therefore none of them were incorporated into the
model.
The data supported the estimation of five diagonal elements of
the Ω matrix. In order to test the presence of covariance between
the diagonal elements, the corresponding correlation coefficients
were computed from the full Ω matrix obtained in the
nonparametric step. All correlation coefficients were below 0.3,
with the exception of the ones corresponding to CL versus F and
kb versus kc, with values of 0.52 and 0.53, respectively. When
those two off-diagonal elements were tested in NONMEM®, both
Absorption (depot)
compartment
Central
compartment
Vc
ka = kb × e–kc × In(t)   Lag time, F
Shallow peripheral
compartment
Vp1
Deep peripheral
compartment
Vp2
CL
Fig. 2. Schematic representation of the model describing serum lanreotide
kinetics after intravenous or deep subcutaneous administration. CL = total
serum clearance; F = total bioavailability; ka = first-order rate constant of
absorption; kb = value of the ka 24 h after administration; kc = first-order
rate constant governing the exponential decrease in the kb as a function of
ln(t); t = time after drug administration; Vc = apparent volume of distribution
of the central compartment; Vp1 = apparent volume of distribution of the
shallow peripheral compartment; Vp2 = apparent volume of distribution of
the deep peripheral compartment.
were non-significant (p > 0.05).
and first-order absorption processes, did not perform significantly Table III lists the population model parameter estimates of the
better than model 6 (table II). selected population pharmacokinetic model represented in figure
2. All parameters were estimated with good precision and, whenThree additional absorption models were also tested, and all of
them fitted the data significantly better than model 6 (first-order
absorption model). Model 9, where the ka was modelled as a
function of time after administration, represented the best model,
with a decrease in the MOFV of 27 and 269 points with respect to
the Weibull model (model 7) and the transit compartment model
(model 8), respectively. In model 9, the ka was modelled as an
exponential decrease (to prevent the ka from being negative) using
equation 1:
ka = kb × e–kc × 1n(t)
(Eq. 1)
where kb is the value of the ka 24 hours after administration, kc is
the first-order rate constant governing the exponential decrease in
the kb as a function of ln(time) and t represents the time after drug
administration. Model 9 provided a decrease in the MOFV of
264.7 points with respect to the model where the ka was modelled
as equation 2:
ka = kb × e–kc × t
(Eq. 2)
The inclusion of a lag time and incomplete absolute bioavaila-
bility (F) were both significant (p < 0.01). The data supported the
incorporation of IIV on F, kb and kc (p < 0.01) in addition to CL
and Vp1. A different estimation of the variance in the additive
residual error between the intravenous and subcutaneous data was
included in the model. Figure 2 represents the model structure
corresponding to model 9 in table II and shows all of the estimated
parameters in the model.
Table III. Population pharmacokinetic model parameter estimates of lan-
reotide in healthy subjects after rapid bolus intravenous administration of
an immediate-release formulation of lanreotide and after deep subcutane-
ous administration of lanreotide Autogel®
Parameter Estimatea IIV [%CV]a
CL [L/d] 554 (0.045) 20 (0.24)
Vc [L] 5.29 (0.12) NE
CLD1 [L/d] 358 (0.14) NE
Vp1 [L] 4.99 (0.19) 38 (0.43)
CLD2 [L/d] 51.4 (0.12) NE
Vp2 [L] 4.86 (0.06) NE
kb [d–1] 0.038 (0.12) 42 (0.32)
kc [d–1] 0.079 (0.30) 96 (0.58)
Lag time [d] 0.036 (0.03) NE
Bioavailability [%] 63 (0.09) 30 (0.27)
Residual error (SD) – intravenous 0.21 (0.053) NA
Residual error (SD) – subcutaneous 0.31 (0.02) NA
a Values in parentheses are relative standard errors.
CL = total serum clearance; CLD1 = distribution clearance between the
central and shallow peripheral compartments; CLD2 = distribution
clearance between the central and deep peripheral compartments; IIV =
interindividual variability; kb = first-order rate constant of absorption 24 h
after administration; kc = first-order rate constant governing the
exponential decrease in the kb as a function of ln(time); NA = not
applicable; NE = not estimated in the model; SD = standard deviation in log
scale; Vc = apparent volume of distribution of the central compartment;
Vp1 = apparent volume of distribution of the shallow peripheral
compartment; Vp2 = apparent volume of distribution of the deep peripheral
compartment.
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Fig. 3. Results of the internal visual predictive check, showing individual serum concentration-time profiles following a rapid intravenous (IV) bolus dose of
7 µg/kg of the immediate-release formulation (IRF) of lanreotide (a) or deep subcutaneous (SC) administration of lanreotide Autogel® at doses of
60 mg (b), 90 mg (c) or 120 mg (d). The solid lines represent the median concentration-time profiles obtained from 1000 model-based simulations. The
dashed lines represent the area covering 95% of the simulated observations. LLQ = lower limit of quantification.
they were compared with those computed using the results from Autogel® administration was 63% and showed moderate IIV
the nonparametric step, the differences were negligible. (30%). The parameter governing the decrease in the ka as a
function of ln(time) was associated with a high value of IIV (96%),Figures 3 and 4 show the results of the internal visual predictive
resembling the variability observed in the serum concentration-check, where it can be observed that the selected model is capable
time profiles (figure 1).of describing the mean tendency of the data, as well as the
observed variability. The plot in figure 5 representing the results of Figure 6a represents the typical profile of the ka versus time
the external visual predictive check suggests that the absorption after drug administration predicted by the model. This figure
and disposition properties of lanreotide Autogel® are very similar shows that the selected model, with a relatively simple equation,
between healthy subjects and acromegalic patients. could account for the initial fast subcutaneous release, where the
ka achieves the highest values during the first days of treatment,The results of the predictive check are shown in table IV,
followed by prolonged release from the depot, where the ka wasconfirming the adequacy of the model to capture two important
approximately constant from day 10 to the end of the study.data descriptors such as the Cmax and AUClast. It should be noted
that in the case of intravenous administration, the dose of lanreo- In figure 6b, the typical model predicting lanreotide serum
tide was adjusted by bodyweight (mean bodyweight in fe- concentration-time profiles during 1 year of treatment with lanreo-
males = 58.8 kg; mean bodyweight in males = 74.7 kg), which tide Autogel® administered subcutaneously once monthly at doses
explains the 30% decrease in the AUC in females. of 60, 90 and 120 mg is presented.[8] The predicted mean Cmin
values at steady state (1.80, 2.70 and 3.60 ng/mL for the 60, 90 andThe total value of the apparent volume of distribution, calculat-
120 mg doses, respectively) were similar to those observed ined as the sum of the apparent volumes of distribution of the
patients with acromegaly at the same three dose levels (1.949,central, shallow peripheral and deep peripheral compartments, was
2.685 and 3.575 ng/mL, respectively). It should be noted that after15.14 L, a value lower than the physiological water volume. The
four once-monthly lanreotide Autogel® injections, the fraction ofestimate of CL was 23.1 L/h and its IIV was approximately 20%.
The absolute bioavailability after deep subcutaneous lanreotide steady state achieved was approximately 94%.
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Fig. 4. Results of the internal visual predictive check, showing individual serum concentration-time profiles during the first hours after rapid intravenous (IV)
bolus administration of the immediate-release formulation (IRF) of lanreotide (a) and during the first week after deep subcutaneous (SC) administration of
lanreotide Autogel® at doses of 60 mg (b), 90 mg (c) or 120 mg (d). The solid lines represent the median concentration-time profiles obtained from 1000
model-based simulations. The dashed lines represent the area covering 90% of the simulated observations. LLQ = lower limit of quantification.
Discussion parameters for extended-release formulations and justifies the
design used in the current study where, during the first period,
This study represents the first population pharmacokinetic ana- lanreotide was given as an intravenous bolus.
lysis of lanreotide Autogel® in which parameters representing Disposition of lanreotide in serum could be described using a
disposition in serum and absorption processes were estimated and standard three-compartment open model; however, the model for
the IIV was quantified.
absorption required some elaboration.
The disposition parameters of lanreotide after rapid intravenous
Lanreotide acetate can form three-dimensional ordered struc-bolus administration of 7 µg/kg have been characterized previous-
tures (liquid crystals) at high concentrations in water, and lanreo-ly using a noncompartmental approach in 12 healthy subjects; CL
tide Autogel® is a simple formulation comprising lanreotide ace-
was 17 L/h,[9] a value slightly lower than that in the current
tate in water for injection at 0.246 mg of active base per milligram
analysis (23.1 L/h). It is possible that such a discrepancy might
of formulation.[22,23] When lanreotide Autogel® has been extravas-have been caused by differences in the design (e.g. sampling
cularly injected, the contact of the formulation with the physiolog-times, number of subjects) and the methodology of the data
ical medium is thought to cause precipitation (depot formation).analysis. IIV could only be estimated in CL and Vp1 and was of
Burst control and prolonged release of lanreotide Autogel® overmoderate-to-low variability. Renal elimination seems to be impor-
>4 weeks was achieved because of the immediate formation of thistant for lanreotide[9] and may account for the low estimate of the
depot at the injection site, resulting in a slow release into thevariability in CL (20%).
circulation from the depot by passive diffusion.The value of CL, together with the small apparent volume of
Different absorption models were fitted to the data[15-17] and,distribution, is responsible for the rapid decline in serum lanreo-
finally, a modification of the standard first-order input model,tide concentrations following an intravenous bolus injection.[20]
where the absorption rate decreases exponentially as a function ofWhen lanreotide was injected as extended-release formulations,
the natural logarithm of time, was selected. The inclusion of onlysuch as micro-particles or Autogel®, a flip-flop situation oc-
curred.[21] This phenomenon prevents estimation of the disposition one extra parameter in the absorption model allows the description
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of the two sequential absorption phases: (i) the initial fast subcuta- from the depot by passive diffusion according to a slow pseudo
neous release, in which the drug that had not precipitated was first-order constant rate (see figure 6a). This model resembles the
immediately absorbed into the bloodstream during the first days of physical changes occurring in the lanreotide Autogel® formulation
treatment; and (ii) the prolonged release of the active compound within the depot compartment when it has been subcutaneously
injected. The limited initial burst release and controlled release
over several weeks after administration at the three dose levels
(60, 90 and 120 mg) demonstrated the robustness of the drug
release from the formulation.
Although one might expect a difference in the bioavailability
and rate of absorption due to differences in body composition
between males and females at the injection site, no clinically
relevant covariate effects of sex were found. A similar result was
found recently after subcutaneous administration of recombinant
human growth hormone.[24] The lack of involvement of body-
weight and sex in the IIV of population pharmacokinetic para-
meters of this model supports the use of fixed dosing and confirms
the appropriateness of the deep subcutaneous route of administra-
tion for both sexes.
Our population model has been validated. Usually, because of
the lack of new data, only internal validation is performed. In this
study, an external validation method was also performed. The new
data came from a study in which patients with acromegaly re-
ceived the same doses as in the current analysis, but given in a
multiple-dosing schedule (once every 4 weeks).[19] The visual
inspection of figure 5 confirms that the model that was developed
adequately captures the mean tendency as well as the dispersion of
the data. This result indicates also that the pharmacokinetics of
lanreotide Autogel® do not differ between healthy subjects and
patients with acromegaly, and that they are independent of time
after the start of treatment.
Figure 7 is the result of the combination of the population
pharmacokinetic model selected in the present study and the
population pharmacodynamic model established recently,[8] and
allows an exploration of the mean and dispersion of steady-state
response-time profiles. These model predictions indicate that after
administration of lanreotide Autogel® (120 mg every 28 days) at
this steady state, approximately 53% of patients with acromegaly
will have a controlled growth hormone level (<2.5 ng/mL)
throughout the dosing interval. In addition, in the clinical study
performed in patients with acromegaly,[8] it was established that a
typical serum lanreotide concentration of 1.13 ng/mL reduced
serum growth hormone levels to <2.5 ng/mL. Taking into account
the model predictions for the Cmin at steady state (Cmin,ss), the
percentage of subjects who would achieve lanreotide concentra-
tions higher than this threshold at steady state are 69%, 86% and
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Fig. 5. Results of the external visual predictive check, showing individual
serum concentration-time profiles (depicted as solid circles) after deep
subcutaneous (SC) administration of lanreotide Autogel® at doses of
60 mg (a), 90 mg (b) or 120 mg (c). The solid lines represent the median
concentration-time profile obtained from 1000 model-based simulations.
The dashed lines represent the area covering 90% of the simulated obser-
vations. The arrows indicate the drug administration times.
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Table IV. Results from the predictive check obtained from 1000 simulations with the selected population pharmacokinetic model
Lanreotide Cmax (ng/mL) AUClast (ng • day/mL)
dose observeda simulatedb observeda simulatedb
female male female male
7 µg/kg 0.72 1.0 Female: 0.74 (0.68, 0.8)
Male: 0.94 (0.88, 1.01)
60 mg 3.2 5.1 4.8 (2.5, 10) 64.5 74.3 61.6 (44, 83.5)
90 mg 5.1 11.2 8 (3.6, 13.8) 97.4 115.7 95.4 (68.6, 129.6)
120 mg 6.1 7.5 8.6 (4.7, 16.6) 127.3 137 133.7 (96.3, 178.7)
a Values are expressed as mean.
b Mean with 2.5th and 97.5th percentiles in parentheses.
AUClast = area under the serum concentration-time curve from time zero to the time of last measurable concentration; Cmax = maximum serum
concentration.
92% for 60, 90 and 120 mg, respectively, administered every provide therapeutically effective drug concentrations at steady
28 days. state. Simulation after repeated lanreotide Autogel® injections at a
dose of 120 mg every 56 days was performed using the pharmaco-Mean lanreotide concentrations remain higher than 0.44, 0.54
kinetic model that was developed (figure 8). The predicted Cmin,ssor 0.81 ng/mL at 56 days after a single lanreotide Autogel®
(1.14 ng/mL [95% CI 0.19, 2.64]) was slightly lower than theinjection of 60, 90 or 120 mg, respectively. These results suggest
predicted drug concentration after 60 mg every 28 days (1.80 ng/that extending the dosing interval from 28 to 56 days could
mL [95% CI 0.48, 3.04]), showing that 81% of subjects treated
with 120 mg every 56 days will have lanreotide concentrations
higher than 0.48 ng/mL (the lower CI limit after 60 mg every
28 days). The mean predicted lanreotide concentration (1.14 ng/
mL) is in the same range as that found in a clinical study of
patients with active acromegaly (1.6 ng/mL), in which effective-
ness was demonstrated with 120 mg of lanreotide Autogel® every
56 days.[25] In addition, 95% of subjects treated with 120 mg every
56 days will have Cmin,ss values higher than the lanreotide concen-
tration that produced a 50% decrease in the maximum reduction in
growth hormone (EC50; 0.206 ng/mL) established in a previous
publication.[8] These findings provide evidence that it is feasible to
extend the dosing interval for lanreotide Autogel® 120 mg to
56 days (1.14 ng/mL) to achieve a response in the growth hormone
reduction similar to that achieved after 60 mg every 28 days. The
primary benefit will be a substantial reduction in the number of
lanreotide Autogel® injections required to achieve a therapeutic
effect.[8]
Conclusions
The disposition characteristics of lanreotide administered as a
rapid intravenous bolus injection of 7 µg/kg were best described
with a three-compartment open model. Estimates of IIV were
moderate (<40%). The total apparent volume of distribution
(15.1 L) was lower than the physiological water volume, and the
estimate of CL was 23.1 L/h.
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tion for longer-term treatment, with administration at least every
4 weeks. The rate and extent of absorption of lanreotide after deep
subcutaneous Autogel® injection was not dependent on the admin-
istered dose in the range of 60–120 mg. The bioavailability was
63% of the administered dose and showed low IIV (27%). No
clinically relevant relationship with any of the demographic
covariates that were tested (age, bodyweight, sex, dose level) was
found in the absorption and disposition properties.
The model-based simulations provide evidence that it may be
clinically feasible to extend the dosing interval for lanreotide
Autogel®. A dose of 120 mg given every 56 days would achieve a
similar response in growth hormone reduction to that achieved
with 60 mg every 28 days.
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Fig. 7. Simulated response-time profiles after the last administration of
6 months’ treatment of deep subcutaneous lanreotide Autogel® 120 mg
every 28 days. The solid line corresponds to the median of the simulated
response-time after last dose profiles, and the dashed lines represent the
5th and 95th percentiles of the simulated response data. The dotted line
shows the value corresponding to controlled growth hormone concentra-
tions (<2.5 ng/mL).
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